Abu Dhabi’s Department of Health and M42 signed an MOU with Mammoth Biosciences to support preclinical CRISPR-based development for severe hypertriglyceridemia and familial chylomicronemia syndrome, advancing Mammoth’s MB-111 program in Abu Dhabi. The partners also plan to establish manufacturing capabilities locally, beginning with lipid nanoparticles for liver delivery, and to build workforce training around CRISPR. The agreement extends the region’s rare-disease and genome-editing capacity-building strategy, positioning Abu Dhabi as a site for translational development and early manufacturing scale-up.